21 – 30 of 112
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
ESMO Clinical Practice Guideline interim update on the use of targeted therapy in acute lymphoblastic leukaemia
- Contribution to journal › Article
-
Mark
Post hoc analysis of ADAMANT, a phase 2 clinical trial of active tau immunotherapy with AADvac1 in patients with Alzheimer’s disease, positive for plasma p-tau217
- Contribution to journal › Article
-
Mark
Defining neuroblastoma : From origin to precision medicine
- Contribution to journal › Scientific review
-
Mark
Revival of recombinant IL-2 therapy–approaches from the past until today
- Contribution to journal › Scientific review
- 2023
-
Mark
HLA Class I Genotype Is Associated with Relapse Risk after Allogeneic Stem Cell Transplantation for NPM1-Mutated Acute Myeloid Leukemia
- Contribution to journal › Article
-
Mark
Examination of the Protein Drug Supply Chain in a Swedish University Hospital : Focus on Handling Risks and Mitigation Measures
- Contribution to journal › Article
-
Mark
Restoring antitumor immunity with dendritic cell reprogramming strategies. Reprogramming cancer cells to antigen-presenting cells.
(2023) In Lund University, Faculty of Medicine Doctoral Dissertation Series
- Thesis › Doctoral thesis (compilation)
-
Mark
Неоадъювантная химиоиммунотерапия у пациентов раком желудка с микросателлитной нестабильностью
- Contribution to journal › Article
-
Mark
Priorities in Cardio-Oncology Basic and Translational Science : GCOS 2023 Symposium Proceedings: JACC: CardioOncology State-of-the-Art Review
- Contribution to journal › Scientific review
-
Mark
Editorial : Biomarkers in the era of cancer immunotherapy: zooming in from the periphery to the tumor microenvironment
- Contribution to journal › Debate/Note/Editorial
